Summary
Global Markets Direct’s, ‘Diarrhea - Pipeline Review, H2 2016’, provides an overview of the Diarrhea pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Diarrhea
- The report reviews pipeline therapeutics for Diarrhea by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diarrhea therapeutics and enlists all their major and minor projects
- The report assesses Diarrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diarrhea
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diarrhea
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diarrhea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
A. Menarini Industrie Farmaceutiche Riunite Srl
Ache Laboratorios Farmaceuticos S/A
Actelion Ltd
Aegis Therapeutics, LLC
AlbireoPharma
Allergan Plc
Anatara Lifesciences Limited
Ardelyx, Inc.
Assembly Biosciences, Inc.
Codagenix, Inc.
Cosmo Pharmaceuticals
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Diarrhea Overview 8
Therapeutics Development 9
Pipeline Products for Diarrhea - Overview 9
Pipeline Products for Diarrhea - Comparative Analysis 10
Diarrhea - Therapeutics under Development by Companies 11
Diarrhea - Therapeutics under Investigation by Universities/Institutes 13
Diarrhea - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Diarrhea - Products under Development by Companies 17
Diarrhea - Products under Investigation by Universities/Institutes 20
Diarrhea - Companies Involved in Therapeutics Development 21
A. Menarini Industrie Farmaceutiche Riunite Srl 21
Ache Laboratorios Farmaceuticos S/A 22
Actelion Ltd 23
Aegis Therapeutics, LLC 24
AlbireoPharma 25
Allergan Plc 26
Anatara Lifesciences Limited 27
Ardelyx, Inc. 28
Assembly Biosciences, Inc. 29
Codagenix, Inc. 30
Cosmo Pharmaceuticals S.p.A 31
DesignMedix, Inc. 32
DiscoveryBiomed, Inc. 33
Genextra S.p.a. 34
GlaxoSmithKline Plc 35
GP Pharm, S.A. 36
Mucosis B.V. 37
Nippon Shinyaku Co., Ltd. 38
Novartis AG 39
Pfizer Inc. 40
Prokarium Limited 41
Protagonist Therapeutics Inc. 42
Rebiotix Inc. 43
Recce Pty Ltd 44
RxBio, Inc. 45
Scandinavian Biopharma Holding AB 46
Sigmoid Pharma Limited 47
Summit Therapeutics Plc 48
Synthetic Biologics, Inc. 49
Syntiron LLC 50
Tasly Pharmaceutical Group Co., Ltd. 51
Diarrhea - Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Target 53
Assessment by Mechanism of Action 56
Assessment by Route of Administration 59
Assessment by Molecule Type 61
Drug Profiles 63
ABM-101 - Drug Profile 63
ACH-04 - Drug Profile 64
ASP-7147 - Drug Profile 65
cadazolid - Drug Profile 66
Campylobacter jejuni [strain CPS81-176] vaccine - Drug Profile 68
cholestyramine - Drug Profile 70
Clostridium difficile vaccine - Drug Profile 71
crofelemer DR - Drug Profile 72
Drug for Diarrhea - Drug Profile 75
eluxadoline - Drug Profile 76
Escherichia coli vaccine - Drug Profile 80
ETEC vaccine - Drug Profile 81
ETEC vaccine - Drug Profile 82
Etvax - Drug Profile 83
GVXNSD-133 - Drug Profile 85
GXG-8 - Drug Profile 86
ibodutant - Drug Profile 87
IMSUTMR-1501 - Drug Profile 88
infectious diarrhea [serotype H11] vaccine - Drug Profile 89
LJN-452 - Drug Profile 90
obeticholic acid - Drug Profile 91
octreotide acetate - Drug Profile 102
octreotide acetate MAR - Drug Profile 103
Peptide to Activate NHE-3 for Diarrhea - Drug Profile 104
PF-06425090 - Drug Profile 105
prulifloxacin - Drug Profile 107
PZ-7475 - Drug Profile 109
RBX-2660 - Drug Profile 110
RDX-98940 - Drug Profile 113
RECCE-355 - Drug Profile 114
Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea - Drug Profile 115
Recombinant Proteins for Infectious Diarrhea - Drug Profile 116
ribaxamase - Drug Profile 117
ridinilazole - Drug Profile 122
rifamycin CR - Drug Profile 127
Rx-100 - Drug Profile 129
Small Molecule to Block CFTR for Diarrhoea - Drug Profile 131
Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 132
Small Molecules for Microbial Infections - Drug Profile 133
Small Molecules to Inhibit Beta-Glucuronidase for Chemotherapy Induced Diarrhea - Drug Profile 134
Small Molecules to Inhibit CFTR for Secretory Diarrhea - Drug Profile 135
SYN-006 - Drug Profile 136
SYN-007 - Drug Profile 137
Synthetic Peptide for Irritable Bowel Syndrome with Diarrhea - Drug Profile 138
Typhetec - Drug Profile 139
Vaccine 1 for Diarrhea - Drug Profile 140
Vaccine 2 for Diarrhea - Drug Profile 141
Vaccine for Traveler's Diarrhea - Drug Profile 142
Vaccine for Traveler's Diarrhea - Drug Profile 143
Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler's Diarrhea - Drug Profile 144
Yersinia pestis vaccine - Drug Profile 145
Diarrhea - Dormant Projects 146
Diarrhea - Discontinued Products 149
Diarrhea - Product Development Milestones 150
Featured News & Press Releases 150
Appendix 159
Methodology 159
Coverage 159
Secondary Research 159
Primary Research 159
Expert Panel Validation 159
Contact Us 159
Disclaimer 160
List of Tables
Number of Products under Development for Diarrhea, H2 2016 13
Number of Products under Development for Diarrhea - Comparative Analysis, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Number of Products under Development by Companies, H2 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2016 17
Comparative Analysis by Late Stage Development, H2 2016 18
Comparative Analysis by Clinical Stage Development, H2 2016 19
Comparative Analysis by Early Stage Development, H2 2016 20
Products under Development by Companies, H2 2016 21
Products under Development by Companies, H2 2016 (Contd..1) 22
Products under Development by Companies, H2 2016 (Contd..2) 23
Products under Investigation by Universities/Institutes, H2 2016 24
Diarrhea - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2016 25
Diarrhea - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016 26
Diarrhea - Pipeline by Actelion Ltd, H2 2016 27
Diarrhea - Pipeline by Aegis Therapeutics, LLC, H2 2016 28
Diarrhea - Pipeline by AlbireoPharma, H2 2016 29
Diarrhea - Pipeline by Allergan Plc, H2 2016 30
Diarrhea - Pipeline by Anatara Lifesciences Limited, H2 2016 31
Diarrhea - Pipeline by Ardelyx, Inc., H2 2016 32
Diarrhea - Pipeline by Assembly Biosciences, Inc., H2 2016 33
Diarrhea - Pipeline by Codagenix, Inc., H2 2016 34
Diarrhea - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2016 35
Diarrhea - Pipeline by DesignMedix, Inc., H2 2016 36
Diarrhea - Pipeline by DiscoveryBiomed, Inc., H2 2016 37
Diarrhea - Pipeline by Genextra S.p.a., H2 2016 38
Diarrhea - Pipeline by GlaxoSmithKline Plc, H2 2016 39
Diarrhea - Pipeline by GP Pharm, S.A., H2 2016 40
Diarrhea - Pipeline by Mucosis B.V., H2 2016 41
Diarrhea - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016 42
Diarrhea - Pipeline by Novartis AG, H2 2016 43
Diarrhea - Pipeline by Pfizer Inc., H2 2016 44
Diarrhea - Pipeline by Prokarium Limited, H2 2016 45
Diarrhea - Pipeline by Protagonist Therapeutics Inc., H2 2016 46
Diarrhea - Pipeline by Rebiotix Inc., H2 2016 47
Diarrhea - Pipeline by Recce Pty Ltd, H2 2016 48
Diarrhea - Pipeline by RxBio, Inc., H2 2016 49
Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H2 2016 50
Diarrhea - Pipeline by Sigmoid Pharma Limited, H2 2016 51
Diarrhea - Pipeline by Summit Therapeutics Plc, H2 2016 52
Diarrhea - Pipeline by Synthetic Biologics, Inc., H2 2016 53
Diarrhea - Pipeline by Syntiron LLC, H2 2016 54
Diarrhea - Pipeline by Tasly Pharmaceutical Group Co., Ltd., H2 2016 55
Assessment by Monotherapy Products, H2 2016 56
Number of Products by Stage and Target, H2 2016 58
Number of Products by Stage and Mechanism of Action, H2 2016 61
Number of Products by Stage and Route of Administration, H2 2016 64
Number of Products by Stage and Molecule Type, H2 2016 66
Diarrhea - Dormant Projects, H2 2016 150
Diarrhea - Dormant Projects (Contd..1), H2 2016 151
Diarrhea - Dormant Projects (Contd..2), H2 2016 152
Diarrhea - Discontinued Products, H2 2016 153
List of Figures
Number of Products under Development for Diarrhea, H2 2016 13
Number of Products under Development for Diarrhea - Comparative Analysis, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Number of Products under Investigation by Universities/Institutes, H2 2016 17
Comparative Analysis by Late Stage Development, H2 2016 18
Comparative Analysis by Clinical Stage Development, H2 2016 19
Comparative Analysis by Early Stage Products, H2 2016 20
Assessment by Monotherapy Products, H2 2016 56
Number of Products by Top 10 Targets, H2 2016 57
Number of Products by Stage and Top 10 Targets, H2 2016 57
Number of Products by Top 10 Mechanism of Actions, H2 2016 60
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 60
Number of Products by Routes of Administration, H2 2016 63
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 63
Number of Products by Top 10 Molecule Types, H2 2016 65
Number of Products by Stage and Top 10 Molecule Types, H2 2016 65
